← Back to Search

Monoclonal Antibodies

GB5121 for Central Nervous System Lymphoma (STAR CNS Trial)

Phase 1

Waitlist Available

Research Sponsored by GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose up to approximately 36 months

Awards & highlights

STAR CNS Trial Summary

This trial is testing a new drug to see if it is safe and effective against cancer.

Eligible Conditions

Central Nervous System Lymphoma

STAR CNS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first dose up to approximately 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first dose up to approximately 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose up to approximately 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Phase 1b Dose Escalation - Dose Limiting Toxicity(ies)

Phase 1b Dose Escalation - Incidence of Adverse Events

Phase 1b Dose Escalation - Optimal Biologic Dose and/or Maximum Tolerated Dose and Recommended Phase 2 Dose

+4 more

Secondary outcome measures

Phase 1b Dose Expansion - Objective Response Rate According to IPCG Criteria by Investigator Assessment

Phase 2 - Confirmed Complete Response by BICR Committee

Phase 2 - Duration of Response by BICR Committee

+6 more

STAR CNS Trial Design

1Treatment groups

Experimental Treatment

Group I: GB5121Experimental Treatment1 Intervention

GB5121 orally twice per day (BID)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Lead Sponsor

Renee Ward, MD, PhDStudy DirectorGB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

8 Previous Clinical Trials

159 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study still enrolling new participants?

"Yes, this is an ongoing study that was originally posted on May 24th, 2020. The most recent update to the listing was on October 14th, 2020."

Answered by AI

How many sites are conducting this research?

"As of right now, this clinical trial is actively recruiting patients from 4 locations. Those interested can go to Phoenix, Jacksonville, Rochester or the 4 other sites for further information. Keep in mind that it might be more convenient to select a site closer to your home to limit travel time if you do decide to participate."

Answered by AI

What is the total sample size for this clinical research?

"That is correct. The information available on clinicaltrials.gov affirms that this trial is still looking for eligible patients. This trial was originally posted on May 24th, 2022 and has been edited as recently as October 14th, 2022. In total, 158 individuals are needed across 4 locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

2022. "GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05242146.